Initial results from a clinical trial show that a drug called tolebrutinib can significantly slow down disability progression in people with secondary progressive MS who no longer experience relapses.
The study recruited 1,131 participants with non-relapsing (non-active) secondary progressive MS. Participants were randomised with some taking tolebrutinib and others taking a placebo (a dummy drug) for up to four years.
Initial results from the study showed that significantly fewer people on tolebrutinib experienced worsening of disability which persisted for six months than those on placebo. Overall, tolebrutinib was found to slow down disability progression by 31% when compared to the placebo.
The study also looked at disability improvement that was sustained for six months. 10% of participants on tolebrutinib saw improvements in their disability compared to 5% on the placebo.
Lastly, tolebrutinib-treated participants saw a 38% reduction in active lesions when compared to the placebo.
You can read the full details of these results on the MS Trust website.
